Alto Neuroscience, Inc. (ANRO)

USD 3.64

(-3.96%)

EBITDA Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual EBITDA in 2023 was -34.56 Million USD , down -29.76% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly EBITDA in 2024 Q1 was -14.28 Million USD , down -20.48% from previous quarter.
  • Alto Neuroscience, Inc. reported an annual EBITDA of -27.36 Million USD in 2022, down -142.21% from previous year.
  • Alto Neuroscience, Inc. reported an annual EBITDA of -9.04 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported a quarterly EBITDA of -18.24 Million USD for 2024 Q2, down -20.11% from previous quarter.
  • Alto Neuroscience, Inc. reported a quarterly EBITDA of -9.02 Million USD for 2023 Q2, down -26.84% from previous quarter.

Annual EBITDA Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual EBITDA of Alto Neuroscience, Inc. (2023 - 2021)

Year EBITDA EBITDA Growth
2023 -34.56 Million USD -29.76%
2022 -27.36 Million USD -142.21%
2021 -9.04 Million USD 0.0%

Peer EBITDA Comparison of Alto Neuroscience, Inc.

Name EBITDA EBITDA Difference
ADC Therapeutics SA -146.76 Million USD 76.45%
Annovis Bio, Inc. -45.03 Million USD 23.255%
Biohaven Pharmaceutical Holding Company Ltd. -429.13 Million USD 91.946%
Ginkgo Bioworks Holdings, Inc. -821.29 Million USD 95.792%
Nuvation Bio Inc. -99.6 Million USD 65.299%
Nuvation Bio Inc. -99.6 Million USD 65.299%
Arcus Biosciences, Inc. -283 Million USD 87.787%
Theriva Biologics, Inc. -19.85 Million USD -74.081%
Zymeworks Inc. -129.95 Million USD 73.405%